Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $56.57M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.63M
Average 0.42M
CRBP Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $49K fell 39.5% year over year, ahead of the -57.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -46.1% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -39.5% holds above the trailing-twelve-month pace of -57.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 233K USD
- Year-over-year change
- -61.2%
- 4-year CAGR
- -38.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 233K | -61.2% |
| FY2024 | 2024-12-31 | 600K | -6.4% |
| FY2023 | 2023-12-31 | 641K | -56.9% |
| FY2022 | 2022-12-31 | 1.49M | -9.2% |
| FY2021 | 2021-12-31 | 1.64M | — |
Depreciation & Amortization vs competitors
How CRBP compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -57.2% is the lowest of 10, against a peer median of +9.7%.
- Over three fiscal years its annual growth of -46.1% compares with a peer median of +8.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.8M USD | +4.8% | +4.5% | 47.8% | |
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $3.2M USD | -40.7% | +41.5% | — | |
| LTM Mar 2026 | CHF 2.61M CHF | +9.7% | -3.5% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $1.14M USD | -2.3% | +2.2% | — |
| LTM Mar 2026 | $1.03M USD | +94.7% | +56.5% | 196.6% | |
| LTM Mar 2026 | $810K USD | -21.4% | +18.0% | 25.6% | |
| LTM Mar 2026 | $248K USD | -57.2% | -46.1% | — | |
| LTM Mar 2026 | $143K USD | +37.5% | +8.6% | 8.0% | |
| LTM Mar 2026 | $70K USD | +62.8% | +21.1% | — | |
| Peer median (excluding CRBP) | — | +9.7% | +8.6% | 47.8% | |
Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 881.71K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.64M | 1.49M | 0 | 600K | 0 |
| Gross Profit | (757.53K) | (1.49M) | 0 | (600K) | 0 |
| Gross Margin | -85.9% | — | — | — | — |
| Research & Development | 36.45M | 16.14M | 31.17M | 32.22M | 70.1M |
| Selling, General & Admin | 20.43M | 18.7M | 13.91M | 16.5M | 15.22M |
| Operating Expenses | 55.23M | 33.35M | 45.08M | 48.12M | 85.31M |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | 600K | 233K |
| EBITDA | (42.17M) | (38.73M) | (40.11M) | (37.74M) | (78.3M) |
| EBITDA Margin | -4782.9% | — | — | — | — |
| Operating Income | (55.99M) | (34.84M) | (45.08M) | (48.72M) | (85.31M) |
| Operating Margin | -6350.1% | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 6.31M | 5.53M |
| Interest Expense | 1.83M | 2.13M | 2.92M | 1.87M | 0 |
| Other Income / Expenses | 10.35M | (7.51M) | 474K | 8.51M | 6.77M |
| Income Before Tax | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Pre-Tax Margin | -5176.4% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (45.55M) | (55.83M) | (44.6M) | (40.21M) | (78.54M) |
| Net Margin | -5166.4% | — | — | — | — |
| EPS (Basic) | (11.13) | (10.15) | (10.31) | (3.68) | (5.90) |
| EPS (Diluted) | (11.13) | (10.15) | (10.31) | (3.68) | (5.90) |
| Weighted Avg Shares | 4.1M | 4.17M | 4.33M | 10.92M | 13.32M |
| Weighted Avg Shares (Diluted) | 4.1M | 4.17M | 4.33M | 10.92M | 13.32M |
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.